There is so much debate about clinical pathways. Some propose that they are an excellent way to reduce variability in clinical care and reduce cost, but others contend that they take away from the clinical judgment and bind physicians into algorithms that do not represent all the patients they care for.
To discuss the pros and cons of clinical pathways, I interviewed Bobby Daly, MD, MBA from Memorial Sloan Kettering Cancer Center. Bobby breaks down prevalent touch points in oncology clinical pathways, including conflicts of interest on pathway development panels, potential for cost variation due to site of care, and interoperability challenges between vendor pathways and individual EMRs.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
